HCPLive
According to the American College of Cardiology, the focus at ACC.13 will be on "the transformation of cardiovascular care — from discovery to delivery." Educational content at ACC.13 will be organized in 16 "learning pathways" that feature "topics ranging from congenital to intervention, imaging to heart failure, prevention to quality care and all the topics in between."
American College of Cardiology ACC.13

American College of Cardiology ACC.13 | ACC 2013

Conference Coverages

Shared-Care Treatment Aids Heart Failure in Older Patients
Shared-Care Treatment Aids Heart Failure in Older Patients
For older adults at risk of heart failure, B-type natriuretic peptide (NP)-guided screening and shared-care treatment is associated with a reduction in the prevalence of left ventricular dysfunction and heart failure.
Ranolazine Relieves Chest Pain in Type 2 Diabetes
Ranolazine reduces chest pain in patients with type 2 diabetes and angina, according to a study presented at ACC.13.
High-Dose Vitamins Don't Reduce Cardiac Events
For adults with previous myocardial infarction, high-dose oral vitamin and mineral supplementation is not associated with a reduction in cardiac events, according to a study presented at ACC.13.
Patient Preference-Based Heart Treatment Improves Depression
A centralized, patient preference-based program for depression care decreases symptoms in patients with post-acute coronary syndrome (ACS), according to a study published online March 7 in JAMA Internal Medicine.
Digoxin Cuts 30-Day Admission for Heart Failure
For older adults with heart failure and reduced ejection fraction, digoxin is associated with a significant reduction in 30-day all-cause hospital admission, with no significant effect on mortality.
VIDEO: Worldwide SHIFT Study Trumps Predecessors on Link Between Heart Rate, Heart Failure Success
Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study’s value for cardiologists over various recent heart failure trials.
VIDEO: Beta Blocker Tolerability, Efficacy Key in Selection, But Vary Across Drugs
Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.

Most Popular

$vacMongoViewPlus$ $vAR$